GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Stock Based Compensation

BrightPath Biotherapeutics Co (TSE:4594) Stock Based Compensation : 円0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co Stock Based Compensation?

BrightPath Biotherapeutics Co's Stock Based Compensation for the three months ended in Dec. 2023 was 円0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.00 Mil.


BrightPath Biotherapeutics Co Stock Based Compensation Historical Data

The historical data trend for BrightPath Biotherapeutics Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co Stock Based Compensation Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 14.01 0.87 - - -

BrightPath Biotherapeutics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BrightPath Biotherapeutics Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.


BrightPath Biotherapeutics Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of BrightPath Biotherapeutics Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


BrightPath Biotherapeutics Co (TSE:4594) Business Description

Traded in Other Exchanges
N/A
Address
2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co (TSE:4594) Headlines

No Headlines